Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • NeuroSciences Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Saudi Medical Journal
  • Other Publications
    • NeuroSciences Journal
  • My alerts
  • Log in
Saudi Medical Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
LetterCorrespondence
Open Access

Comment on: Evaluation of early biomarkers of renal dysfunction in diabetic patients

Abdulghani H. Alsaeed
Saudi Medical Journal October 2020, 41 (10) 1147; DOI: https://doi.org/10.15537/smj.2020.10.25399
Abdulghani H. Alsaeed
Endocrinology & Diabetes Department Prince Sultan Military Medical City Riyadh, Kingdom of Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

To the Editor

I have read with a great interest the article of “Evaluation of early biomarkers of renal dysfunction in diabetic patients” by Al-Hazmi et al.1

Diabetic nephropathy is one of the microvascular complications of diabetes mellitus. It has been linked to increase mortality in patients with diabetes mellitus.2 The surge of mortality in these patients progresses with the advancement of diabetic nephropathy.3 The standard biomarker of diabetic nephropathy is urine albumin/creatinine ratio. So, finding novel biomarkers that might detect the kidney damage early is a crucial advancement in medicine that might lead to early treatment and prevention of the disease progression.

The main result of the study was the significant increase of the studied biomarkers (urinary neutrophil gelatinase-associated lipocalin [uNGAL], urinary N-acetyle-beta-D-glucosaminidase [uNAG], and serum Cystatin C) in patients with diabetes mellitus and severely albuminuria as compared to those with moderately increased albuminuria, normal albuminuria, and normal control. This finding was similarly found in previous studies.4,5 Additionally, the study came with a very interesting finding that the level of uNGAL was significantly higher in the group with diabetes mellitus and normal albuminuria as compared to normal control. The authors have indicated that such result might allude to early discovery of kidney injury in patients with diabetes. Such result is fascinating, and it might open the door for researches in the future regarding the early discovery and management of diabetic nephropathy.

There were several drawbacks on the study, first the sample size was small. Secondly, there was no matching point between the 4 groups. For example, all the groups had different age, duration of diabetes and different glycemic control which might contribute to differences in the results. Furthermore, the medications which might affect the albumin secretion were not included in the study like ACEi, ARB, or sGLT2i. Finally, the issue of having a significant difference between a new biomarker in patients with normal albuminuria might not indicate an early disease since there no histological study to confirm that patients were suffering diabetic nephropathy. I agree such result creates a hypothesis, but on the other hand, it might simply mean that the biomarker is not specific.

In conclusion, diabetic nephropathy is a nasty complication of diabetes mellitus with an increase morbidity and mortality that necessitate early discovery of novel markers. The uNGAL might a be good biomarker to detect early renal dysfunction. However, a larger, and a well-organized study is needed in the future to validate their use in clinical practice.

Reply from the Author

No reply was received from the Author.

  • Copyright: © Saudi Medical Journal

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

  1. ↵
    1. Al-Hazmi SF,
    2. Gad HG,
    3. Alamoudi AA,
    4. Eldakhakhny BM,
    5. Binmahfoozv SK,
    6. Alhozali AM
    (2020) Evaluation of early biomarkers of renal dysfunction in diabetic patients. Saudi Med J 41:690–697.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Afkarian M,
    2. Sachs MC,
    3. Kestenbaum B,
    4. Hirsch IB,
    5. Tuttle KI,
    6. Himmelfarb J,
    7. et al.
    (2013) Kidney disease and increased mortality risk in type 2 Diabetes. J Am Soc Nephrol 24:302–308.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Bentata Y,
    2. Haddiya I,
    3. Latrech H,
    4. Serraj K
    (2013) Progression of diabetic nephropathy, risk of end-stage renal disease and mortality in patients with type-1 diabetes. Saudi J Kidney Dis Transpl 24:392–402.
    OpenUrlPubMed
  4. ↵
    1. Siddiqi Z,
    2. Karoli R,
    3. Kaul A,
    4. Fatima J,
    5. Varshney S,
    6. Beg MS
    (2017) Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as early markers of diabetic nephropathy. Ann Afr Med 16:101–106.
    OpenUrl
  5. ↵
    1. Chena B,
    2. Lib Y,
    3. Liua Y,
    4. Zanga C,
    5. Wua M,
    6. Xu Z
    (2019) Diagnostic value of neutrophil gelatinase-associated lipocalin in diabetic nephropathy:a meta-analysis. Renal Failure 41:489–496.
    OpenUrl
PreviousNext
Back to top

In this issue

Saudi Medical Journal: 41 (10)
Saudi Medical Journal
Vol. 41, Issue 10
1 Oct 2020
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Saudi Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comment on: Evaluation of early biomarkers of renal dysfunction in diabetic patients
(Your Name) has sent you a message from Saudi Medical Journal
(Your Name) thought you would like to see the Saudi Medical Journal web site.
Citation Tools
Comment on: Evaluation of early biomarkers of renal dysfunction in diabetic patients
Abdulghani H. Alsaeed
Saudi Medical Journal Oct 2020, 41 (10) 1147; DOI: 10.15537/smj.2020.10.25399

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comment on: Evaluation of early biomarkers of renal dysfunction in diabetic patients
Abdulghani H. Alsaeed
Saudi Medical Journal Oct 2020, 41 (10) 1147; DOI: 10.15537/smj.2020.10.25399
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • References
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Management of trigger finger (stenosing tenosynovitis)
  • Comment on: Post surgical hypoparathyroidism
  • Overcoming socioeconomic obstacles is important in achieving equity in health care
Show more Correspondence

Similar Articles

CONTENT

  • home

JOURNAL

  • home

AUTHORS

  • home
Saudi Medical Journal

© 2025 Saudi Medical Journal Saudi Medical Journal is copyright under the Berne Convention and the International Copyright Convention.  Saudi Medical Journal is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3175. Print ISSN 0379-5284.

Powered by HighWire